KELSEY GILLIAM: Open Payments
NPI 1932876455 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,097 in 190 payments from 23 companies in 2025. Trend: 2023 $148 · 2024 $2,069 · 2025 $2,097
Food & beverage: $2,097
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 45 | $332 |
| ABBVIE INC. | 57 | $322 |
| Lilly USA, LLC | 20 | $257 |
| Novo Nordisk Inc | 21 | $199 |
| AstraZeneca Pharmaceuticals LP | 3 | $199 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $175 |
| Sumitomo Pharma America, Inc. | 8 | $137 |
| GlaxoSmithKline, LLC. | 4 | $75 |
| Medtronic, Inc. | 2 | $60 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $47 |
Products named: XIFAXAN, AIRSUPRA, MOUNJARO, NURTEC ODT, GEMTESA, ELIQUIS, Ozempic, UBRELVY.
Industry payments across KS — which companies pay providers there.
